Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.
Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The June 2003 monograph topics are aprepitant, gemifloxacin, desirudin for injection, gatifloxacin ophthalmic solution, and pegvisomant. The DUE is on aprepitant.
Get full access to this article
View all access options for this article.
References
1.
Humira [package literature].Abbott Laboratories; December 20, 2002.
den BroederA.A.Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: Effect on radiologic course and prognostic value of markers of cartilage turnover and endothelial activation.Ann Rheum Dis.2002; 61: 311–8.
4.
SalfeldJ.Generation of fully human anti-TNF antibody D2E7 [abstract].Arthritis Rheum.1998; 41(9 suppl): S57.
5.
KempeniJ.Update on D2E7: A fully human anti-tumour necrosis factor alpha monoclonal antibody.Ann Rheum Dis.2000; 59(suppl 1): i44–5.
6.
BarreraP.Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNF-alpha in patients with rheumatoid arthritis.Ann Rheum Dis.2001; 60: 660–9.
7.
den BroederA.A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis.J Rheumatol.2002; 29: 2288–98.
8.
VelagapudiR.B.Pharmacokinetics of adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, following a single intravenous injection in rheumatoid arthritis patients treated with methotrexate [abstract 261]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
9.
KeystoneE.The ARMADA trial: A double-blind placebo controlled trial of the fully human anti-TNF monoclonal antibody, adalimumab (D2E7), in patients with active RA on methotrexate (MTX) [abstract].Arthritis Rheum.2001; 44(9, suppl 1): S213.
10.
KeystoneE.The fully human anti-TNF monoclonal antibody, adalimumab (D2E7), dose ranging study: The 24-week clinical results in patients with active RA on methotrexate therapy (the ARMADA trial) [abstract OP0086]. European Congress of Rheumatology EULAR 2001; June 13–16, 2001; Prague. www.eular.org. Accessed May 14, 2002.
11.
FurstD.TNF blockade by the fully human monoclonal antibody, adalimumab (D2E7), in the ARMADA trial results in decreases in serum matrix metalloproteinase (MMP) levels along with impressive clinical improvement in refractory RA patients [abstract].Arthritis Rheum.2001; 44(9, suppl 1): S215.
12.
StrandV.Treatment with adalimumab (D2E7), a fully human anti-TNF monoclonal antibody, improves physical function and health related quality of life (HRQOL) in patients with active rheumatoid arthritis (RA) [abstract FRI0049]. European Congress of Rheumatology EULAR 2002; June 12–15, 2002; Stockholm. www.eular.org. Accessed May 14, 2002.
13.
KavanaughA.F.The ARMADA trial: Twelve-month efficacy and safety of combination therapy with adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, and methotrexate (MTX) in patients with active rheumatoid arthritis [abstract FRI0026]. European Congress of Rheumatology EULAR 2002; June 12–15, 2002; Stockholm. www.eular.org. Accessed May 14, 2002.
14.
KeystoneE.Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract 468]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
15.
WellborneF.Adalimumab (D2E7), a fully human anti-TNF-a monoclonal antibody, improved health-related quality of life in patients with active rheumatoid arthritis despite concomitant methotrexate therapy [abstract 1384]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
16.
BreedveldF.C.The fully human anti-TNF antibody adalimumab (D2E7) in combination with methotrexate (MTX) in the treatment of active rheumatoid arthritis: Results of a 2-year study [abstract OP0062]. European Congress of Rheumatology EULAR 2001; June 13–16, 2001; Prague. www.eular.org. Accessed May 14, 2002.
17.
RauR.2.5-Year treatment results with adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, in combination with methotrexate in active rheumatoid arthritis [abstract OP0073]. European Congress of Rheumatology EULAR 2002; June 12–15, 2002; Stockholm. www.eular.org. Accessed May 14, 2002.
18.
van RielP.L.C.Long-term treatment with adalimumab (D2E7) using background methotrexate in active rheumatoid arthritis: Results of a 3-year study [abstract 1428]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
19.
WeismanM.A dose escalation study designed to demonstrate the safety, tolerability and efficacy of the fully human anti-TNF antibody, D2E7, given in combination with methotrexate (MTX) in patients with active RA [abstract].Arthritis Rheum.2001; 43(9, suppl): S391.
20.
SchiffM.A randomized, controlled, safety trial of adalimumab (D2E7), a fully human anti-TNF monoclonal antibody, given to RA patients in combination with standard rheumatologic care: The STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) trial [abstract FRI0028]. European Congress of Rheumatology EULAR 2002; June 12–15, 2002; Stockholm. www.eular.org. Accessed May 14, 2002.
21.
FurstD.E.Efficacy of adalimumab (D2E7), a fully human anti-TNF monoclonal antibody, administered to rheumatoid arthritis patients in combination with other antirheumatic therapy in the STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) trial [abstract FRI0045]. European Congress of Rheumatology EULAR 2002; June 12–15, 2002; Stockholm. www.eular.org. Accessed May 14, 2002.
22.
FurstD.E.Safety and efficacy of adalimumab (D2E7), a fully human anti-TNF-a monoclonal antibody, given in combination with standard antirheumatic therapy: Safety Trial of Adalimumab in Rheumatoid Arthritis (STAR) [abstract 1537]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
23.
Van de PutteL.B.A.Efficacy and safety of adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, in patients with rheumatoid arthritis who failed previous DMARD therapy: 6-month results from a phase III study [abstract FRI0027]. European Congress of Rheumatology EULAR 2002; June 12–15, 2002; Stockholm. www.eular.org. Accessed May 14, 2002.
24.
van de PutteL.B.A.Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis [abstract 370]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
25.
BurmesterG.R.Two-year experience with adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, in patients with DMARD-refractory rheumatoid arthritis [abstract FRI0160]. European Congress of Rheumatology EULAR 2002; June 12–15, 2002; Stockholm. www.eular.org. Accessed May 14, 2002.
26.
RevickiD.Treatment with adalimumab (D2E7), a fully human anti-TNF monoclonal antibody, improves physical function, vitality, and mental health while reducing bodily pain in patients with active rheumatoid arthritis (RA) [abstract 1437]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
27.
BurmesterG.R.Long-term efficacy and safety of adalimumab (D2E7) monotherapy in patients with DMARD-refractory rheumatoid arthritis—Results from a 2-year study [abstract 1436]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
28.
Van de PutteL.B.A.Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis [abstract].Arthritis Rheum.1999; 42(9, suppl): S400.
29.
Van de PutteL.B.A.One-year efficacy results of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis [abstract].Arthritis Rheum.2000; 43(9, suppl): S269.
30.
EmeryP.Changes in pro-MMP-1 in relation to standard measures of disease activity over a 6 months treatment period with adalimumab (D2E7) in rheumatoid arthritis [abstract].Arthritis Rheum.2001; 44(9, suppl 1): S215.
31.
SchattenkirchnerM.Long-term use of the fully human anti-TNF antibody adalimumab (D2E7) in DMARD-refractory rheumatoid arthritis [abstract OP0083]. European Congress of Rheumatology EULAR 2001; June 13–16, 2001; Prague. www.eular.org. Accessed May 14, 2002.
32.
Van de PutteL.B.A.A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis [abstract].Arthritis Rheum.1998; 41(9, suppl): S57.
33.
RauR.Long-term efficacy and tolerability of multiple IV doses of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis [abstract].Arthritis Rheum.1998; 41(9, suppl): S55.
34.
RauR.Long-term treatment with the fully human anti-TNF-antibody D2E7 slows radiographic disease progression in rheumatoid arthritis [abstract].Arthritis Rheum.1999; 42(9, suppl): S400.
35.
den BroederA.A.Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-α.Rheumatology.2002; 41: 638–42.
36.
WellsA.F.Incidence of injection-site reactions associated with adalimumab (D2E7) given subcutaneously for at least 6 months: A retrospective analysis of 4 phase II/III clinical trials [abstract 370]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
37.
KavanaughA.F.Treatment with adalimumab (D2E7) does not affect normal immune responsiveness [abstract 259]. 66th Annual Scientific Meeting of the American College of Rheumatology; October 25–29, 2002.
38.
Humira Medicare Assistance Program. Abbott Laboratories. Abbott Park, IL: 02K-640–5282–5. December 2002.
